

TruTouch Technologies Signs Clinical Trial Agreement with Lovelace Respiratory Research Institute & Lovelace Scientific Resources for Clinical Trial of Next-Generation Alcohol Intoxication Screening Device

The Associated Press

FRAMINGHAM, Mass. & ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Oct 16, 2012--TruTouch Technologies, a pioneer in non-invasive alcohol intoxication and biometric measurement systems, today announced that it has signed a Clinical Trial agreement for the next generation of the Company's alcohol screening device with Lovelace Respiratory Research Institute (LRRI) and Lovelace Scientific Resources (LSR), an Albuquerque, N.M.-based, FDA-approved contract research organization.

The agreement calls for LRRI/LSR to work with TruTouch in the Correlation & Calibration of the TruTouch 2500 workplace sobriety assurance device, a tabletop instrument that can detect tissue alcohol concentration by directly measuring alcohol levels through the skin, using a safe infrared light and an optical touch pad. The device also features biometric capability to verify user identity to ensure integrity of the testing process. The TruTouch 2500 system is being commercialized for workplace deployment, medical and point of sale applications.

Dr. Trent Ridder, CTO of TruTouch Technologies, said, "We are delighted to select LRRI/LSR as the CRO partner for the TruTouch 2500 instrument, which represents a major advance over current invasive, time consuming, cumbersome and consumables-based alcohol detection solutions. Our selection of LRRI/LSR was due to its expertise in timely, high-quality and exacting clinical trials, as well as its extensive experience executing clinical trials for FDA-approval. Additionally, as TruTouch explores potential future commercialization plans in clinical settings, LRRI/LSR's clear experience with medical device clinical trials will be of benefit." Dr. Richard D. Gill, President and CEO of TruTouch Technologies, added, "The TruTouch 2500 represents what we feel is the first practicable solution for large-scale alcohol intoxication detection and interception systems in work environments. The touch detection capability is a major advance as the device can enable inexpensive, ongoing, large-scale daily testing of employees at point of need. The biometric identity verification also allows the test to be safely self-administered, without need for supervision." Bob Rubin, President and CEO of LRRI/LSR, noted, "It is our pleasure to work closely with the TruTouch team to help bring their next-generation product line to market through our LSR CRO Clinical Trial Services. Enabling disruptive innovation is our core mission, and our team is looking forward to supporting TruTouch's go-to-market strategy through our Clinical capabilities." TruTouch systems can be seamlessly incorporated into workflow, and reporting tools allow management of networked and multi-site installations. The resulting reports generate integrated testing records that are not readily available from other

TruTouch Technologies Signs Clinical Trial Agreement with Lovelace Respiratory Research Institute

Published on Medical Design Technology (<http://www.mdtmag.com>)

testing approaches. During the last four years, TruTouch devices have completed more than 750,000 tests for customers. Published peer-reviewed clinical studies show a 96% correlation to forensic grade blood test results, which are also as accurate as conventional, evidentiary grade systems such as breathalyzers.

About Lovelace Respiratory Research Institute/Lovelace Scientific Resources The Lovelace Respiratory Research Institute and its subsidiary, Lovelace Scientific Resources, undertake state-of-the-art research and development in numerous clinical and preclinical settings, with over 1,000 trials and other protocols under active investigation at any one time. With over 250 current partners, 40 drugs under active development, a full discovery complement of peer reviewed NIH funded work and 65 years of research experience, Lovelace represents one of the most dynamic active private research enterprises in the country.

About TruTouch Technologies TruTouch Technologies, Inc. develops, manufactures and sells patented noninvasive alcohol intoxication and biometric testing systems, which provide companies with the only realistic, truly effective deterrent system available for unobtrusive verification of sobriety on a daily or routine basis. Inspired by the potential to place its passive, durable systems virtually anywhere, TruTouch's vision is to create a world where intoxication is routinely intercepted before it does harm. For more information please visit www.trutouchtechnologies.com.

CONTACT: Matter Communications Emily Snyder, 978-518-4507 cell: 508-932-1427 esnyder@matternow.com KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW MEXICO INDUSTRY KEYWORD: TECHNOLOGY HARDWARE HEALTH CLINICAL TRIALS MEDICAL DEVICES PROFESSIONAL SERVICES HUMAN RESOURCES RESEARCH FDA SCIENCE SOURCE: TruTouch Technologies, Inc. Copyright Business Wire 2012 PUB: 10/16/2012 10:15 AM/DISC: 10/16/2012 10:15 AM <http://www.businesswire.com/news/home/20121016005259/>

Source URL (retrieved on 01/28/2015 - 8:42am):

<http://www.mdtmag.com/news/2012/10/trutouch-technologies-signs-clinical-trial-agreement-lovelace-respiratory-research-institute-lovelace-scientific-resources-clinical-trial-next-generation-alcohol-intoxication-screening-device>